Spyre Therapeutics (SYRE) Operating Margin (2015 - 2023)
Spyre Therapeutics (SYRE) posted Operating Margin of 23146.22% for Q2 2023, down 143.7% on a QoQ basis from 9497.98% in Q1 2023, and down 1955854.0% year-over-year from N/an in Q2 2022.
Spyre Therapeutics (SYRE) Operating Margin (2015 - 2023) Analysis & Trends
Spyre Therapeutics' Operating Margin history runs 7 years deep, the most recent figure standing at 23146.22% for Q2 2023.
- Quarterly Operating Margin fell 1955854.0% year-over-year to 23146.22% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 39428.92% (down 3263528.0% YoY) and the FY2023 annual result came in at 27347.97%, down 2370774.0% from the prior year.
- Operating Margin was 23146.22% for Q2 2023 at Spyre Therapeutics, down from 9497.98% in the prior quarter.
- Across five years, Operating Margin topped out at 48.96% in Q2 2021 and bottomed at 23146.22% in Q2 2023.
- A 3-year average of 6776.68% and a median of 3587.68% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin slumped 353872 bps — and 2023, when it plunged 1955854 bps.
- Spyre Therapeutics' Operating Margin stood at 560.98% in 2021, then tumbled by 1933 bps to 11405.95% in 2022, then tumbled by 103 bps to 23146.22% in 2023.
- Business Quant data shows SYRE's Operating Margin at 23146.22% in Q2 2023, 9497.98% in Q1 2023, and 11405.95% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -23,146.22% |
| Mar 31, 2023 | -9,497.98% |
| Dec 31, 2022 | -11,405.95% |
| Sep 30, 2022 | -10,778.74% |
| Jun 30, 2022 | -3,587.68% |
| Mar 31, 2022 | -1,794.49% |
| Dec 31, 2021 | -560.98% |
| Sep 30, 2021 | -169.11% |
| Jun 30, 2021 | -48.96% |
| Jun 30, 2018 | -406.64% |
| Mar 31, 2018 | -546.03% |
| Dec 31, 2017 | -446.86% |
| Sep 30, 2017 | -634.26% |
| Jun 30, 2017 | -454.36% |
| Mar 31, 2017 | -644.70% |
| Dec 31, 2016 | -444.51% |
| Sep 30, 2016 | -548.39% |
| Jun 30, 2016 | -400.22% |
| Mar 31, 2016 | -531.66% |
| Dec 31, 2015 | -252.18% |